AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

• Published in: Journal of clinical oncology Vol. 37; no. 14; pp. 1188 - 1199
• Main Authors: Leonard, John P., Trneny, Marek, Izutsu, Koji, Fowler, Nathan H., Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W., Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G.
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 10.05.2019
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Humans; Lenalidomide - administration & dosage; Lenalidomide - adverse effects; Lymphoma, B-Cell, Marginal Zone - drug therapy; Lymphoma, Follicular - drug therapy; Male; Middle Aged; Neoplasm Recurrence, Local - drug therapy; ORIGINAL REPORTS; Placebos; Rituximab - adverse effects; Rituximab - therapeutic use

Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. A phase III, multicenter, randomized trial...